← All trials
NCT06374758
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 29, 2024
- Primary completion
- May 1, 2025
- Completion date
- Nov 1, 2025
- First posted
- Apr 19, 2024
- Last posted
- Oct 9, 2024
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MissouriLead sponsor
- University of MissouriOfficial
- University of MissouriSponsor investigator
- Gilead SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.